Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.49 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105237 | 1.00 | CTSK (0.57) | CTSKITGB3ITGA2BKLK5KLK7 | |
| SCHEMBL6697388 | 0.91 | CTSK (0.57) | CTSKITGB3ITGA2BCTSLCTSS | |
| SCHEMBL6697386 | 0.91 | CTSK (0.57) | CTSKITGB3ITGA2BCTSLCTSS | |
| SCHEMBL4686404 | 0.90 | CTSK (0.70) | CTSKCTSLCTSS | |
| SCHEMBL4686405 | 0.90 | CTSK (0.70) | CTSKCTSLCTSS | |
| SCHEMBL5983043 | 0.89 | CTSK (0.57) | CTSKITGB3ITGA2BKLK5KLK7 | |
| SCHEMBL5983052 | 0.89 | CTSK (0.57) | CTSKITGB3ITGA2BKLK5KLK7 | |
| SCHEMBL5099282 | 0.88 | CTSK (0.57) | CTSKITGB3ITGA2BKLK5KLK7 | |
| SCHEMBL27537673 | 0.88 | CTSK (0.57) | CTSKITGB3ITGA2BKLK5KLK7 | |
| SCHEMBL6580495 | 0.86 | CTSK (0.77) | CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1253441-C | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2006-04-26 | — | — | CN | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885ITGB3 1328/4885ITGA2B 3309/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CTSK 1/4885ITGB3 1846/4885ITGA2B 2948/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885ITGB3 1328/4885ITGA2B 3309/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885ITGB3 1328/4885ITGA2B 3309/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885ITGB3 1328/4885ITGA2B 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.